Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis

The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis

NCT03927352 ·Status: UNKNOWN ·Phase: PHASE3

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

NCT06176508 ·Status: RECRUITING ·Phase: PHASE2

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

NCT02016105 ·Status: COMPLETED ·Phase: PHASE3

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

NCT04064242 ·Status: COMPLETED ·Phase: PHASE2

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice

NCT01077232 ·Status: COMPLETED

Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice

NCT04517669 ·Status: COMPLETED

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

NCT02808975 ·Status: COMPLETED ·Phase: PHASE4

Vascular Inflammation in Psoriasis Trial (The VIP Trial)

NCT01553058 ·Status: COMPLETED ·Phase: PHASE4

Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

NCT00442650 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life

NCT01169987 ·Status: COMPLETED

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

NCT04453137 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa

NCT01468233 ·Status: COMPLETED ·Phase: PHASE3

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00646191 ·Status: COMPLETED ·Phase: PHASE2

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00645814 ·Status: COMPLETED ·Phase: PHASE2

Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)

NCT01076192 ·Status: COMPLETED

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00237887 ·Status: COMPLETED ·Phase: PHASE3

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

NCT00918255 ·Status: COMPLETED ·Phase: PHASE2

Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea

NCT03925441 ·Status: COMPLETED

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

NCT00195689 ·Status: COMPLETED ·Phase: PHASE3

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

NCT05991323 ·Status: ACTIVE_NOT_RECRUITING

To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT05495568 ·Status: COMPLETED ·Phase: PHASE3

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

NCT02660580 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis

NCT00382512 ·Status: COMPLETED ·Phase: PHASE1

Psoriatic Immune Response to Tildrakizumab

NCT05390515 ·Status: UNKNOWN ·Phase: PHASE4

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

NCT01392326 ·Status: COMPLETED ·Phase: PHASE3